Bal Pharma Valuation
Is 524824 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Unter dem Marktwert
Deutlich unter dem Marktwert
Price-To-Earnings gegen Gleichaltrige
Price-To-Earnings gegen Industrie
PM vs. Fair Ratio
Analysten-Prognose
Share Price vs Fair Value
What is the Fair Price of 524824 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Unter dem Marktwert: 524824 (₹118.5) wird über unserer Schätzung des Fair Value (₹11.67) gehandelt.
Deutlich unter dem Marktwert: 524824 über unserer Schätzung des beizulegenden Zeitwerts gehandelt wird.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 524824?
Other financial metrics that can be useful for relative valuation.
| What is 524824's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | ₹1.62b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 0.9x |
| Enterprise Value/EBITDA | 10.8x |
| PEG Ratio | n/a |
Price to Earnings Ratio vs Peers
How does 524824's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 40x | ||
VAISHALI Vaishali Pharma | 30.2x | n/a | ₹1.8b |
524828 BDH Industries | 19.8x | n/a | ₹1.7b |
SOTAC Sotac Pharmaceuticals | 45.8x | n/a | ₹1.4b |
540686 Smruthi Organics | 64.2x | n/a | ₹1.8b |
524824 Bal Pharma | 46.1x | n/a | ₹1.6b |
Price-To-Earnings gegen Gleichaltrige: 524824 ist auf der Grundlage des Price-To-Earnings Verhältnisses (52.8x) im Vergleich zum Durchschnitt der Vergleichsgruppe (32.5x) teuer.
Price to Earnings Ratio vs Industry
How does 524824's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?
Price-To-Earnings gegen Industrie: 524824 ist teuer, wenn man sein Price-To-Earnings Verhältnis (52.8x) mit dem Indian Pharmaceuticals Branchendurchschnitt (34.9x) vergleicht.
Price to Earnings Ratio vs Fair Ratio
What is 524824's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 46.1x |
| Fair PE Ratio | n/a |
PM vs. Fair Ratio: Insufficient data to calculate 524824's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analysten-Prognose: Insufficient data to show price forecast.